Housheng Hansen He
Script error: No such module "Draft topics". Script error: No such module "AfC topic".
| Housheng Hansen He | |
|---|---|
| Born | 1980 |
| 💼 Occupation | |
| 🌐 Website | www |
Housheng Hansen He (born on Dec. 28, 1980) is a senior scientist at the Princess Margaret Cancer Centre, University Health Network, and Professor at the Department of Medical Biophysics, University of Toronto. He studies the epigenetic regulation and noncoding RNA in cancer. In 2022, His research in epigenetic markers and target therapies has earned him the Canadian Cancer Society 2022 Bernard and Francine Dorval Prize[1].
Life and Career[edit]
Housheng Hansen He studied Physics in 1999-2003 at Beijing Normal University. He obtained his PhD in Molecular Biology and Bioinformatics in the laboratory of Runsheng Chen at the Institute of Biophysics, Chinese Academy of Sciences in 2008. Housheng Hansen He then received postdoctoral training under the joint supervision of computational biologist Shirley Liu and cancer biologist Myles Brown at the Dana-Farber Cancer Institute and Harvard University.
Scientific Career[edit]
In September 2013, Housheng Hansen He started his independent career as a Scientist at the Princess Margaret Cancer Centre and Assistant Professor in the Department of Medical Biophysics at the University of Toronto. Housheng Hansen He was promoted to Senior Scientist and associate Professor in 2018, and to professor in 2022.
Housheng Hansen He's laboratory applies a variety of genomic, epigenomic experimental and computational approaches to decipher epigenetic and epitranscriptomic regulation in Cancer, focusing on three major directions: 1. Understand epigenetic and epitranscriptomic regulation in cancer development, progression, drug response and resistance. 2. Identify epigenetic and epitranscriptomic biomarkers in tumor and liquid biopsies. 3. Target cancer specific epigenetic and epitranscriptomic regulation for cancer therapy, with a focus on RNA therapy.
Housheng Hansen He has authored over 100 publications at high profile journals including Nature (2016), Cell (2018, 2019), Nature Genetics (2016, 2020), Nature Cell Biology (2021) and Gastroenterology (2022). The translational research in Housheng Hansen He's laboratory has resulted in one phase II clinical trial and four patents. Housheng Hansen He has received several distinctions and recognitions, including a few new investigator awards from national funding agencies, as well as being named a rising star in prostate cancer research.
He holds the Joey and Toby Tanenbaum Brazilian Ball Chair in Prostate Cancer Research, and Tier 1 Canada Research Chair in RNA Medicine. Dr. He leads the RNA Medicine Initiative and Core at Princess Margaret Cancer Centre. He received 2022 Bernard and Francine Dorval Prize from Canadian Cancer Society. [2]
Media Coverage[edit]
1. Housheng Hansen He's work identify new therapeutic target for colon cancer. Researchers at the Princess Margaret provide new insights into possible therapeutic pathway for colorectal cancer 2. Housheng Hansen He introduces his work on genetic and epigenetic effects in prostate cancer. Like a butterfly's wings 3. Housheng Hansen He introduces his work on genetic risk and noncoding RNA in prostate cancer. Prostate cancer researchers pinpoint key regulatory role of noncoding genes in disease development, progression 4. Housheng Hansen He received a Terry Fox New Investigator Award. Housheng Hansen He
References[edit]
- ↑ "Award-winning scientist Dr. Housheng He is at the forefront of cancer research". Canadian Immigrant. Retrieved 2024-01-03.
- ↑ cancer, Canadian Cancer Society / Société canadienne du. "Awards for Excellence Winners 2022". Canadian Cancer Society. Retrieved 2024-01-03.
External links[edit]
This article "Housheng Hansen He" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Housheng Hansen He. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
